Perioperative immunotherapy for esophageal squamous cell carcinoma: Now and future

Table 3 Clinical trials of adjuvant immunotherapy for resectable esophageal squamous cell carcinoma

Drug	Trial name/No.	Phase	Sample size	Clinical stage	Design	Chemotherapy drugs	Chemotherapy cycles	Radiotherapy	Interval time to surgery	Primary endpoint	Start date	Outcome
Nivolumab	CheckMate-577/NCT02743494	III	784 (ESCC29%)	NA	Two-arm	NA				DFS	Completed	22.1:11.0 mo
Toripalimab (+ Neoadjuvant)	NCT 04437212	II	20	IIB-IVA	Single-arm	PTX + DDP	5, Q3W	41.4 Gy/23 f	6-8 wk	MPR	Jul 1, 2020
Tislelizumab	AIRE/ChiCTR2100045651	III	110	High-risk resected locally advanced	Two-arm	Platinum-based doublets	2, Q3W			DFS	May 1, 2021
Tislelizumab	CRISEC/NCT04776590	II	30	NA	Single-arm	PTX + CBP	5, Q1W	41.4 Gy/23 f		pCR	Jan 28, 2021

DFS: Disease-free survival; NA: Not available; DDP: Cisplatin; PTX: Paclitaxel; CBP: Carboplatin; pCR: Pathological complete response; MPR: Major pathological response.